Login   |  Users Online: 229 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Search Article 
Advanced search 
   Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts

  Table of Contents  
Year : 2012  |  Volume : 33  |  Issue : 4  |  Page : 499-504  

Effects of turmeric on Alzheimer's disease with behavioral and psychological symptoms of dementia

1 Chief Physician, Department of Neurology, Kariya Toyota General Hospital, Kariya City, Aichi, Japan
2 Lecturer, Nippon Ayurveda School, Chuo Ku,Tokyo, Japan
3 Medical staff, Department of Neurology, Kariya Toyota General Hospital, Kariya City, Aichi, Japan
4 Head, Department of Neurology, Kariya Toyota General Hospital, Kariya City, Aichi, Japan
5 Adviser, Department of Neurology, Kariya Toyota General Hospital, Kariya City, Aichi, Japan
6 Principal, Nippon Ayurveda School, Chuo Ku,Tokyo, Japan

Date of Web Publication12-Apr-2013

Correspondence Address:
Nozomi Hishikawa
Department of Neurology, Kariya Toyota General Hospital, 5 15 Sumiyoshi Cho, Kariya City, Aichi 448 8505
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0974-8520.110524

Rights and Permissions

We describe here three patients with the Alzheimer's Disease (AD) whose behavioral symptoms were improved remarkably as a result of the turmeric treatment, which is the traditional Indian medicine. Their cognitive decline and Behavioral and Psychological Symptoms of Dementia (BPSD) were very severe. All three patients exhibited irritability, agitation, anxiety, and apathy, two patients suffer from urinary incontinence and wonderings. They were prescribed turmeric powder capsules and started recovering from these symptoms without any adverse reaction in the clinical symptom and laboratory data. After 12 weeks of the treatment, total score of the Neuro-Psychiatric Inventory-brief questionnaire decreased significantly in both acuity of symptoms and burden of caregivers. In one case, the Mini-Mental State Examination (MMSE) score was up five points, from 12/30 to 17/30. In the other two cases, no significant change was seen in the MMSE; however, they came to recognize their family within 1 year treatment. All cases have been taking turmeric for more than 1 year, re-exacerbation of BPSD was not seen. The present cases suggest a significant improvement of the behavioral symptoms in the AD with the turmeric treatment, leading to probable benefit of the use of turmeric in individuals with the AD with BPSD.

Keywords: Alzheimer′s disease, behavioral and psychological symptoms of dementia, curcumin, mini-mental state examination, neuropsychiatric inventory-brief questionnaire, turmeric

How to cite this article:
Hishikawa N, Takahashi Y, Amakusa Y, Tanno Y, Tuji Y, Niwa H, Murakami N, Krishna U K. Effects of turmeric on Alzheimer's disease with behavioral and psychological symptoms of dementia. AYU 2012;33:499-504

How to cite this URL:
Hishikawa N, Takahashi Y, Amakusa Y, Tanno Y, Tuji Y, Niwa H, Murakami N, Krishna U K. Effects of turmeric on Alzheimer's disease with behavioral and psychological symptoms of dementia. AYU [serial online] 2012 [cited 2023 Mar 24];33:499-504. Available from: https://www.ayujournal.org/text.asp?2012/33/4/499/110524

   Introduction Top

Alzheimer's disease (AD) is the most common form of dementia and it is characterized by the progressive cognitive impairment. The behavioral and psychological symptoms of the dementia (BPSD) are also commonly seen in patients with AD, such as hallucinations, delusions, apathy, depression, agitation, irritability, and wandering. These symptoms can have serious harmful effects on patients' Quality of Life (QOL) and are also a burden to caregivers and increasing the costs of care. [1] Therefore, the treatment of BPSD is as important as that of core symptom such as memory disturbance and disorientation. Acetylcholinesterase (AChE) inhibitors and N-Methyl-d-Aspartate (NMDA) receptor uncompetitive antagonist (memantin hydrochloride) are commonly used for the treatment of AD. They are effective in core symptoms and BPSD treatment; [2],[3],[4] however, the effects are not completely satisfactory. They can cause adverse effects such as nausea, extra-pyramidal symptoms, drowsiness, and the other symptoms.

Neuropathologically, AD is characterized by the presence of senile plaques, neurofibrillary tangles, persistent neuronal loss, although, the neurotoxic mechanisms have not been completely elucidated. It is clear that both oxidative stress and inflammation play a key role in the illness. Recent reports have suggested therapeutic potential of curcumin in the pathophysiology of AD, because of its antioxidant, anti-inflammatory, and anti-amyloid effects. [5],[6],[7],[8],[9],[10],[11] Curcumin is a polyphenolic molecule extracted from turmeric, the spice consisting of the powdered rhizome of the plant Curcuma longa Linn. Turmeric contains about 5% curcumin, which gives the spice its yellow color and is used widely as yellow food coloring. It has also a medical history that date back 5000 years. It has been extensively used to treat various ailments for centuries in Ayurveda, the traditional Indian system of medicine, such as arthritis, gastric ulcer, jaundice, fever, liver disease, urinary tract disease, skin disease, and as a "blood purifier." [12] Many pharmacological studies have been conducted to describe the multiple biological actions of curcumin. Curcumin has also demonstrated neuroprotective effects in animal models of not only AD; [13] however, also Parkinson's disease, [14],[15],[16] depression, [17],[18],[19] epilepsy, [20] and so on. Epidemiological studies in India, a country where turmeric consumption is widespread, suggest that it has one of the lowest prevalence rates of AD in the world. [21],[22] In spite of the high efficacy and safety, curcumin has not yet been approved as a therapeutic agent. Here, we present three cases with the AD whose behavioral symptoms and ability perform Activities of Daily Living (ADL) were improved by turmeric treatment without any adverse effects.

   Case Reports Top

Case 1

The patient was an 83-year-old female who developed progressive dementia. She had started to exhibit disturbances of short-term memory and orientation, when she was 76 years old. There was no past history of diabetes mellitus, hypertension, dyslipidemia, and head injury. The medical family history was unremarkable. She also had difficulty in learning new information. Gradually, her daily activity was disturbed. She had increasing difficulty in getting dressed, cooking, and coordination household tasks. She wandered aimlessly around the house, had incontinence of urine. She had some psychobehavioral changes, such as apathy, anxiety, agitation, and irritability. She required the presence of caregiver, though she was prescribed AChE inhibitor (donepezil 10 mg) and Yokukansan, which is a traditional Japanese medicine (Kampo). When she was 83 years old, she scored on 1/30 her Mini-Mental State Examination (MMSE), which was used for evaluation of cognitive functions. Her physical examination was largely normal. There were no pyramidal or extra-pyramidal signs. Findings on laboratory tests were normal. Cerebral Magnetic Resonance Imaging (MRI) demonstrated symmetrical bilateral temporal atrophy. After turmeric 764 mg/day (curcumin 100 mg/day) treatment for 12 weeks, both scores of acuity of symptoms and burden of caregivers were decreased by the Japanese version of neuropsychiatric inventory-brief questionnaire (NPI-Q) [Table 1], [Figure 1] and [Table 2]. Among the NPI-Q subscales, her agitation, apathy, anxiety, and irritability were relieved. She began to tell about the need to urinate. Furthermore, she came to join in the laughter watching TV comedy program, began to sing some songs and do knitting, which she used to do. After taking turmeric for more than 1 year, she came to recognize her family, and seem to remind her late husband and she lives a peaceful life without a significant BPSD.
Figure 1: Change in the total score of acuity of symptoms on the neuropsychiatric inventory-brief questionnaire before and after turmeric treatment of three patients with Alzheimer's disease

Click here to view
Table 1: Change in the score of the Neuropsychiatric Inventory-Brief Questionnaire before and after turmeric treatment in patient with Alzheimer's disease (Case 1)

Click here to view
Table 2: Change in the score of the Neuropsychiatric Inventory-Brief Questionnaire before and after turmeric treatment in patient with Alzheimer's disease (Case 2)

Click here to view

Case 2

An 84-year-old female presented at our hospital with the purpose of taking medical advice for progressive dementia. Her symptoms were forgetfulness, disorientation to place and time, hallucination, delusion, agitation, irritability, depression, apathy, confabulation, wandering, and incontinence of urine, which developed several years prior to presentation. She had a history of hypertension. There was no family history of dementia. She was a non-smoker and drank little alcohol. Her physical examination and her laboratory data, including hematograms, biochemistry, and urinalysis were largely normal. At the time of her initial visit, her cognitive decline was already very severe and her MMSE score was 0/30. On cerebral MRI revealed moderate bilateral temporal atrophy with the mild ventricular dilation. AChE inhibitor (donepezil) could not use because of the side-effects. Her BPSD, including agitation, irritability, and anxiety was not improved, though she was prescribed Yokukansan and atypical antipsychotic drugs. We began to administer turmeric 764 mg/day (curcumin 100 mg/day) to her. She gradually calmed down. Her BPSD, which were hallucination, delusion, depression, agitation, apathy, anxiety, and irritability, were relieved. She stopped urinating outside the front door. She came to put on her clothes properly, and distinguish her family from staffs of the care center. After 12 weeks, judging from the Japanese version of NPI-Q, both acuity of BPSD and burden of caregivers were relieved [Table 2], [Figure 1] and [Table 2]. She has been taking turmeric for more than 1 year; she lives in a peacefully serene manner with her family.

Case 3

A 79-year-old male patient presented at our hospital accompanied by his wife. She reported that the short-term memory loss gradually developed over several years, though he was already prescribed AChE inhibitor (donepezil 5 mg) by his previous doctor for 3 years. He wanted to stay at home, and lived an idle life. He stopped painting in oils, which he used to do for his hobby. He had a history of hypertension being treated with losartan potassium. The medical family history was insignificant. His physical examination was normal. Routine blood tests were normal, including thyroid function, serum vitamin B1, B12, and folic acid. Cerebral MRI demonstrated mild bilateral temporal atrophy with mild ischemic changes in deep white matter. Single-Photon Emission Computed Tomography showed typical AD pattern, which means perfusion in the temporal, parietal, and posterior cingulated is significantly decreased. His MMSE score was 12/30, with poor orientation to place and time, calculation, concentration, recall, transcription of the figure, spontaneous writing, and verbal fluency. His BPSD was agitation, depression, apathy, anxiety, euphoria, aberrant eating behavior, and irritability. Turmeric 764 mg/day (curcumin 100 mg/day) treatment for 12 weeks relieved the patient's BPDS, especially agitation, irritability, and depression. Both scores of acuity of symptoms and burden of the caregivers were decreased in the Japanese version of the NPI-Q [Table 3], [Figure 1] and [Figure 2]. His MMSE score was up five points, 17/30, improving calculation, concentration, transcription of the figure, and spontaneous writing. He has been taking turmeric for more than 1 year; he lives calmly with his wife.
Figure 2: Change in the total score of burden of caregivers on the neuropsychiatric inventory-brief questionnaire before and after turmeric treatment of three patients with Alzheimer's disease

Click here to view
Table 3: Change in the score of the Neuropsychiatric Inventory-Brief Questionnaire before and after turmeric treatment in patient with Alzheimer's disease (Case 3)

Click here to view

   Discussion Top

Here, we reported three cases of the AD whose BPSD were a significantly improved by the turmeric treatment, evaluated by the NPI-Q. The NPI-Q is a brief, reliable, and the clinical rating instrument that evaluates the neuronpsychiatric symptoms in demented patients and associated caregiver distress, and the effects of pharmacological treatment on these symptoms and caregivers' distress. [23] Therefore, in this study, we evaluate using the NPI-Q confirmed that turmeric treatment improved the behavioral symptoms associated with AD. The present study found that the turmeric was effective for the treatment of several BPSD, including delusions, hallucination, apathy, agitation, anxiety, irritability, and depression. In all cases, total score of the NPI-Q decreased significantly in both acuity of symptoms and burden of caregivers. Clinical improvements were gradually observed within 12 weeks of turmeric administration. And their caregivers were released from the associated distress. In case 1 and case 3 patients, donepezil was being administered for several years before starting the turmeric treatment, and the effect of donepezil on BPSD may therefore already had reached a stable state. Turmeric did further decrease the NPI-Q score, already decreased by donepezil.

BPSD can impair the QOL in the patient and also their caregiver. There is a positive correlation between severity of BPSD and care burden, and treatment of BPSD is as important as that of core symptoms. [24] AChE inhibitors, [2],[4] NMDA receptor uncompetitive antagonist (memantin), [3] and antipsychotic drugs are effective in BPSD treatment; however, the effects are not completely satisfactory. In particular, antipsychotic drugs can cause adverse effects such as drug-induced extrapyramidal symptoms, drowsiness, gait disturbance, and other symptoms and can result in a decrease on patients' ADL and QOL. In contrast, there were no adverse effects or significant change in laboratory data in our cases during the turmeric treatment. Based on these results, turmeric treatment in AD is safer than other pharmacological treatments and useful for patients, and that it can possibly reduce the doses of antipsychotics required for the treatment of BPSD.

BPSD occur in 50-90% of AD patient, and an imbalance between the different neurotransmitters, such as serotonin, dopamine, glutamine, acetylcholine, and norepinephrine are related to the pathophysiology of BPSD in AD. [25],[26] Curcumin, a major active component of turmeric possesses some interesting properties. Curcumin modulate the levels of norepinephrine, dopamine, and serotonin in the brain, [18],[19] and inhibit of Mono-Amine Oxidase (MAO)-A and MAO-B enzyme, the enzyme that decomposes dopamine and serotonin. [18] Dopamine is involved in pleasure, emotion, and regulating locomotion while serotonin has a major role to play in neurovegetative functions of the body, such as appetite, sleep, memory and learning, temperature regulation, mood, behavior, cardiovascular functions, muscle contraction, and endocrine regulation. Norepinephrine is a neurotransmitter involved in attentiveness, emotions, sleeping, dreaming, and learning. We speculate that turmeric significantly reduces behavioral symptoms of AD patients by modifying these neurotransmitters' dysfunction.

Mounting reports have suggested preventive and/or therapeutic potential of cur cumin and other products from turmeric in the pathophysiology of AD, such as the Amydoid-β (Aβ) cascade, tau phosphorylation, neuroinflammation, or oxidative stress. Several studies have shown that the curcumin are powerful antioxidants, and possess strong anti-inflammatory activity. [7],[27] In vitro studies have shown that curcumin attenuates inflammatory response of brain microglial cells, [28] and inhibits the formation of Aβ oligomers and fibrils. [10],[11] Aβ oligomers are highly toxic, and viewed as playing an important role in AD pathology. [29],[30] In vivo study shows that curcumin can reverse neuritic abnormalities resulting from Aβ production. [8] In transgenic mice model of AD studies, curcumin prevents neuronal damage in the brain, [31] and directly binds small Aβ species to block aggregation and fibril formation. [11] Another study using a transgenic mouse has shown that dietary curcumin significantly lowered oxidized proteins and interleukin-1β, a proinflammatory cytokine in the neuroinflammatory cascades involved in neuritic plaque formation in the brain. [9] And this study also showed that with the curcumin treatment, the astrocytic marker Glial Fibrillary Acidic Protein (GFAP) was reduced, and insoluble and soluble Aβ and plaque burden were significantly decreased by 43-50%.

For the treatment of AD, AChE inhibitors and NMDA receptor uncompetitive antagonist (memantin) are commonly used. Curcumin possess pronounced AChE inhibitory activity in the frontal cortex and hippocampus of AD in experimental animals, [32] and protect against NMDA-induced toxicity in vitro study. [33] Furthermore, curcumin has been reported to increase choline acetyl transferase (ChAT) activity, a synthesizing enzyme for acetylcholine, in the hippocampus of AD model rat. [34] It has been reported that curcumin can be effective in preventing and suppressing cognitive impairment on the grounds that it possess antioxidative, anti-neuroinflammatory effects, and modulate cholinergic system. [35],[36] Epidemiological study showed that increased consumption of curry, which usually contain turmeric, is associated with better cognitive performance in non-demented subjects. [37] However, in a clinical trial in China, 34 patients with probable or possible AD randomized to 4 g (10.9 mmol), 1 g (2.7 mmol), 0 g of turmeric once daily showed no significant differences in changes MMSE score or plasma Aβ40 levels between 0 and 6 months. [38] In our report, one patient improved his MMSE score. In the other two cases, their cognitive declines were too severe to take MMSE; however, they came to recognize their family. The improvement of their cognitive function might be due to the activation of the ChAT and the AChE inhibiter, and/or stabilization of the patient's mental status by turmeric.

We conclude that turmeric treatment adding to the routine therapy increase the QOL and ADL of patients and ease caregivers' burden. This is the first case report demonstrating that turmeric is an effective and safe drug for the treatment of the BPSD in AD patients and that it might impair cognitive function.

   Acknowledgments Top

We would like to gratefully acknowledgment the KANEHIDE BIO Co., LTD., for providing us turmeric.

   References Top

1.Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry 2002;17:403-8.  Back to cited text no. 1
2.Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002;14:389-404.  Back to cited text no. 2
3.Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: A systematic meta-analysis. Ann Pharmacother 2008;42:32-8.  Back to cited text no. 3
4.Paleacu D, Mazeh D, Mirecki I, Even M, Barak Y. Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol 2002;25:313-7.  Back to cited text no. 4
5.Balasubramanian K. Molecular orbital basis for yellow curry spice curcumin's prevention of Alzheimer's disease. J Agric Food Chem 2006;54:3512-20.  Back to cited text no. 5
6.Cole GM, Lim GP, Yang F, Teter B, Begum A, Ma Q, et al. Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging 2005;26 Suppl 1:133-6.  Back to cited text no. 6
7.Cole GM, Morihara T, Lim GP, Yang F, Begum A, Frautschy SA. NSAID and antioxidant prevention of Alzheimer's disease: Lessons from in vitro and animal models. Ann N Y Acad Sci 2004;1035:68-84.  Back to cited text no. 7
8.Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 2007;102:1095-104.  Back to cited text no. 8
9.Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21:8370-7.  Back to cited text no. 9
10.Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 2004;75:742-50.  Back to cited text no. 10
11.Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892-901.  Back to cited text no. 11
12.Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci 2008;65:1631-52.  Back to cited text no. 12
13.Hamaguchi T, Ono K, Yamada M. REVIEW: Curcumin and Alzheimer's disease. CNS Neurosci Ther 2010;16:285-97.  Back to cited text no. 13
14.Jagatha B, Mythri RB, Vali S, Bharath MM. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: Therapeutic implications for Parkinson's disease explained via in silico studies. Free Radic Biol Med 2008;44:907-17.  Back to cited text no. 14
15.Mythri RB, Bharath MM. Curcumin: A potential neuroprotective agent in Parkinson's disease. Curr Pharm Des 2012;18:91-9.  Back to cited text no. 15
16.Rajeswari A, Sabesan M. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice. Inflammopharmacology 2008;16:96-9.  Back to cited text no. 16
17.Kulkarni S, Dhir A, Akula KK. Potentials of curcumin as an antidepressant. Scientific World Journal 2009;9:1233-41.  Back to cited text no. 17
18.Kulkarni SK, Bhutani MK, Bishnoi M. Antidepressant activity of curcumin: Involvement of serotonin and dopamine system. Psychopharmacology (Berl) 2008;201:435-42.  Back to cited text no. 18
19.Xu Y, Ku BS, Yao HY, Lin YH, Ma X, Zhang YH, et al. The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol 2005;518:40-6.  Back to cited text no. 19
20.Jyoti A, Sethi P, Sharma D. Curcumin protects against electrobehavioral progression of seizures in the iron-induced experimental model of epileptogenesis. Epilepsy Behav 2009;14:300-8.  Back to cited text no. 20
21.Chandra V, Pandav R, Dodge HH, Johnston JM, Belle SH, DeKosky ST, et al. Incidence of Alzheimer's disease in a rural community in India: The Indo-US study. Neurology 2001;57:985-9.  Back to cited text no. 21
22.Vas CJ, Pinto C, Panikker D, Noronha S, Deshpande N, Kulkarni L, et al. Prevalence of dementia in an urban Indian population. Int Psychogeriatr 2001;13:439-50.  Back to cited text no. 22
23.Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000;12:233-9.  Back to cited text no. 23
24.Huang SS, Lee MC, Liao YC, Wang WF, Lai TJ. Caregiver burden associated with behavioral and psychological symptoms of dementia (BPSD) in Taiwanese elderly. Arch Gerontol Geriatr 2012;55:55-9.  Back to cited text no. 24
25.Lanari A, Amenta F, Silvestrelli G, Tomassoni D, Parnetti L. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech Ageing Dev 2006;127:158-65.  Back to cited text no. 25
26.Lanctôt KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 2001;13:5-21.  Back to cited text no. 26
27.Zhao BL, Li XJ, He RG, Cheng SJ, Xin WJ. Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Biophys 1989;14:175-85.  Back to cited text no. 27
28.Kim HY, Park EJ, Joe EH, Jou I. Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J Immunol 2003;171:6072-9.  Back to cited text no. 28
29.Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-91.  Back to cited text no. 29
30.Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-9.  Back to cited text no. 30
31.Shukla PK, Khanna VK, Khan MY, Srimal RC. Protective effect of curcumin against lead neurotoxicity in rat. Hum Exp Toxicol 2003;22:653-8.  Back to cited text no. 31
32.Ahmed T, Gilani AH. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol Biochem Behav 2009;91:554-9.  Back to cited text no. 32
33.Matteucci A, Cammarota R, Paradisi S, Varano M, Balduzzi M, Leo L, et al. Curcumin protects against NMDA-induced toxicity: A possible role for NR2A subunit. Invest Ophthalmol Vis Sci 2011;52:1070-7.  Back to cited text no. 33
34.Ishrat T, Hoda MN, Khan MB, Yousuf S, Ahmad M, Khan MM, et al. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol 2009;19:636-47.  Back to cited text no. 34
35.Awasthi H, Tota S, Hanif K, Nath C, Shukla R. Protective effect of curcumin against intracerebral streptozotocin induced impairment in memory and cerebral blood flow. Life Sci 2010;86:87-94.  Back to cited text no. 35
36.Yadav RS, Chandravanshi LP, Shukla RK, Sankhwar ML, Ansari RW, Shukla PK, et al. Neuroprotective efficacy of curcumin in arsenic induced cholinergic dysfunctions in rats. Neurotoxicology 2011;32:760-8.  Back to cited text no. 36
37.Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH. Curry consumption and cognitive function in the elderly. Am J Epidemiol 2006;164:898-906.  Back to cited text no. 37
38.Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008;28:110-3.  Back to cited text no. 38


  [Figure 1], [Figure 2]

  [Table 1], [Table 2], [Table 3]

This article has been cited by
1 Tau-aggregation inhibition: promising role of nanoencapsulated dietary molecules in the management of Alzheimer’s disease
Pramod G. Nagaraju, Ashwini S, Poornima Priyadarshini
Critical Reviews in Food Science and Nutrition. 2022; : 1
[Pubmed] | [DOI]
2 Bioactive Compounds and Their Derivatives: An Insight into Prospective Phytotherapeutic Approach against Alzheimer’s Disease
Fahadul Islam, Jannatul Fardous Khadija, Md. Harun-Or-Rashid, Md. Saidur Rahaman, Mohamed H. Nafady, Md. Rezaul Islam, Aklima Akter, Talha Bin Emran, Polrat Wilairatana, Mohammad S. Mubarak, Sachchida Nand Rai
Oxidative Medicine and Cellular Longevity. 2022; 2022: 1
[Pubmed] | [DOI]
3 A Review on Herbal Remedies for Alzheimer’s Disease
Sarthak Prashant Mehta, Ramachandran Balaraman
Journal of Natural Remedies. 2022; 22(2): 123
[Pubmed] | [DOI]
4 Neuroprotective Potential of Curcuminoids in Modulating Alzheimer’s Disease via Multiple Signaling Pathways
Anam Shabbir, Kanwal Rehman, Moazzama Akbar, Muhammad Sajid Hamid Akash
Current Medicinal Chemistry. 2022; 29(34): 5560
[Pubmed] | [DOI]
5 Pomegranate (Punica granatum L.) Attenuates Neuroinflammation Involved in Neurodegenerative Diseases
Alami Mehdi, Benchagra Lamiae, Boulbaroud Samira, Mhamed Ramchoun, Khalil Abdelouahed, Fulop Tamas, Berrougui Hicham
Foods. 2022; 11(17): 2570
[Pubmed] | [DOI]
6 Neuroprotective Natural Products for Alzheimer’s Disease
Xin Chen,Joshua Drew,Wren Berney,Wei Lei
Cells. 2021; 10(6): 1309
[Pubmed] | [DOI]
7 Beneficial Effects of Epigallocatechin-3-O-Gallate, Chlorogenic Acid, Resveratrol, and Curcumin on Neurodegenerative Diseases
Ryuuta Fukutomi,Tomokazu Ohishi,Yu Koyama,Monira Pervin,Yoriyuki Nakamura,Mamoru Isemura
Molecules. 2021; 26(2): 415
[Pubmed] | [DOI]
8 Therapeutic Potential of Natural Products in Treating Neurodegenerative Disorders and Their Future Prospects and Challenges
Md. Habibur Rahman,Johny Bajgai,Ailyn Fadriquela,Subham Sharma,Thuy Thi Trinh,Rokeya Akter,Yun Ju Jeong,Seong Hoon Goh,Cheol-Su Kim,Kyu-Jae Lee
Molecules. 2021; 26(17): 5327
[Pubmed] | [DOI]
9 Nutrition, Physical Activity, and Other Lifestyle Factors in the Prevention of Cognitive Decline and Dementia
Ligia J. Dominguez, Nicola Veronese, Laura Vernuccio, Giuseppina Catanese, Flora Inzerillo, Giuseppe Salemi, Mario Barbagallo
Nutrients. 2021; 13(11): 4080
[Pubmed] | [DOI]
10 A novel nutritional mixture, MBN, prevents memory impairment via inhibiting NLRP3 inflammasome formation in 5xFAD transgenic mice
Namkwon Kim,Jin Gyu Choi,In Gyoung Ju,Yeon-Joo Ju,Sung-Vin Yim,Jong Kil Lee,Myung Sook Oh
Nutritional Neuroscience. 2021; : 1
[Pubmed] | [DOI]
11 Thioredoxin-interacting protein (TXNIP) as a target for Alzheimer’s disease: flavonoids and phenols
Meng Zhang,Guanhua Hu,Nan Shao,Yunpeng Qin,Qian Chen,Yan Wang,Peng Zhou,Biao Cai
Inflammopharmacology. 2021;
[Pubmed] | [DOI]
12 Plant Natural Products as Neuroprotective Nutraceuticals: Preclinical and Clinical Studies and Future Implications
Abhijit Dey,Samapika Nandy,Anuradha Mukherjee,Devendra Kumar Pandey
Proceedings of the National Academy of Sciences, India Section B: Biological Sciences. 2020;
[Pubmed] | [DOI]
13 Redox modifications in synaptic components as biomarkers of cognitive status, in brain aging and disease
Pablo Muñoz,Álvaro O. Ardiles,Boris Pérez-Espinosa,Cristian Núñez-Espinosa,Andrea Paula-Lima,Christian González-Billault,Yolanda Espinosa-Parrilla
Mechanisms of Ageing and Development. 2020; 189: 111250
[Pubmed] | [DOI]
14 Natural Products and Their Bioactive Compounds: Neuroprotective Potentials against Neurodegenerative Diseases
Nur Shafika Mohd Sairazi,K. N. S. Sirajudeen
Evidence-Based Complementary and Alternative Medicine. 2020; 2020: 1
[Pubmed] | [DOI]
15 Prevention of Cognitive Decline in Alzheimer’s Disease by Novel Antioxidative Supplements
Koh Tadokoro,Yasuyuki Ohta,Haruhiko Inufusa,Alan Foo Nyuk Loon,Koji Abe
International Journal of Molecular Sciences. 2020; 21(6): 1974
[Pubmed] | [DOI]
16 Obstacles against the Marketing of Curcumin as a Drug
Kambiz Hassanzadeh,Lucia Buccarello,Jessica Dragotto,Asadollah Mohammadi,Massimo Corbo,Marco Feligioni
International Journal of Molecular Sciences. 2020; 21(18): 6619
[Pubmed] | [DOI]
17 Functional Foods: An Approach to Modulate Molecular Mechanisms of Alzheimer’s Disease
Anna Atlante,Giuseppina Amadoro,Antonella Bobba,Valentina Latina
Cells. 2020; 9(11): 2347
[Pubmed] | [DOI]
18 Molecular Mechanism of Autophagy: Its Role in the Therapy of Alzheimer’s Disease
Yuan Zhao,Yidan Zhang,Jian Zhang,Xiangjian Zhang,Guofeng Yang
Current Neuropharmacology. 2020; 18(8): 720
[Pubmed] | [DOI]
19 Curcuminoids and Novel Opportunities for the Treatment of Alzheimeræs Disease: Which Molecules are Actually Effective?
Alexander V. Zholos,Olesia F. Moroz,Maksim V. Storozhuk
Current Molecular Pharmacology. 2019; 12(1): 12
[Pubmed] | [DOI]
20 Natural Compounds as Beneficial Antioxidant Agents in Neurodegenerative Disorders: A Focus on Alzheimer’s Disease
Antonella Amato,Simona Terzo,Flavia Mulè
Antioxidants. 2019; 8(12): 608
[Pubmed] | [DOI]
21 Supplementation with Curcuma longa Reverses Neurotoxic and Behavioral Damage in Models of Alzheimer’s Disease: A Systematic Review
Ianara Mendonça da Costa,Marco Aurelio de Moura Freire,José Rodolfo Lopes de Paiva Cavalcanti,Dayane Pessoa de Araújo,Bianca Norrara,Isleânia Maria Marques Moreira Rosa,Eduardo Pereira de Azevedo,Amália Cinthia Meneses do Rego,Irami Araújo Filho,Fausto Pierdoná Guzen
Current Neuropharmacology. 2019; 17(5): 406
[Pubmed] | [DOI]
22 Effects of Curcumin on Cognitive Function—A Systematic Review of Randomized Controlled Trials
Nathan Seddon,Nathan M. D’Cunha,Duane D. Mellor,Andrew J. McKune,Ekavi N. Georgousopoulou,Demosthenes B. Panagiotakos,Jane Kellett,Nenad Naumovski
Exploratory Research and Hypothesis in Medicine. 2019; 4(1): 1
[Pubmed] | [DOI]
23 Safflower (Carthamus tinctorius L.) seed attenuates memory impairment induced by scopolamine in mice via regulation of cholinergic dysfunction and oxidative stress
Ji Hyun Kim,Mei Tong He,Min Jo Kim,Chang Yeol Yang,Yu Su Shin,Takako Yokozawa,Chan Hum Park,Eun Ju Cho
Food & Function. 2019;
[Pubmed] | [DOI]
24 Impedimetric Approach for Estimating the Presence of Metanil Yellow in Turmeric Powder from Tunable Capacitance Measurement
Chirantan Das,Subhadip Chakraborty,Nirmal Kumar Bera,Krishnendu Acharya,Dipankar Chattopadhyay,Anupam Karmakar,Sanatan Chattopadhyay
Food Analytical Methods. 2019;
[Pubmed] | [DOI]
25 The impact of curcumin and its modified formulations on Alzheimeræs disease
Tahereh Farkhondeh,Saeed Samarghandian,Ali Mohammad Pourbagher-Shahri,Mahshid Sedaghat
Journal of Cellular Physiology. 2019;
[Pubmed] | [DOI]
26 Curcuma Longa Treatment Effect on Blood Samples of Rat with Hepatic Damage: A Photoacoustic Spectroscopy Application
M. L. Alvarado-Noguez,P. Rojas-Franco,E. Cano-Europa,M. Franco-Colín,C. Hernández-Aguilar,F. A. Domínguez-Pacheco,A. Cruz-Orea,F. Sánchez-Sinencio
International Journal of Thermophysics. 2018; 39(9)
[Pubmed] | [DOI]
27 Efficacy of curcumin for age-associated cognitive decline: a narrative review of preclinical and clinical studies
Marjana Rahman Sarker,Susan F. Franks
GeroScience. 2018;
[Pubmed] | [DOI]
28 The therapeutic potential of curcumin: A review of clinical trials
Bahare Salehi,Zorica Stojanovic-Radic,Jelena Matejic,Mehdi Sharifi-Rad,Nanjangud V. Anil Kumar,Natália Martins,Javad Sharifi-Rad
European Journal of Medicinal Chemistry. 2018;
[Pubmed] | [DOI]
29 Targeting BDNF modulation by plant glycosides as a novel therapeutic strategy in the treatment of depression
Haroon Khan,Surriya Amin,Seema Patel
Life Sciences. 2018; 196: 18
[Pubmed] | [DOI]
30 The neuroprotective effects of an ethanolic turmeric (Curcuma longa L.) extract against trimethyltin-induced oxidative stress in rats
Sapto Yuliani,Sapto Mustofa,Ginus Partadiredja
Nutritional Neuroscience. 2018; : 1
[Pubmed] | [DOI]
31 Can Curcumin Counteract Cognitive Decline? Clinical Trial Evidence and Rationale for Combining ?-3 Fatty Acids with Curcumin
Julia Christina Kuszewski,Rachel Heloise Xiwen Wong,Peter Ranald Charles Howe
Advances in Nutrition. 2018; 9(2): 105
[Pubmed] | [DOI]
32 Amphiphilic Nanocarrier Systems for Curcumin Delivery in Neurodegenerative Disorders
Miora Rakotoarisoa,Angelina Angelova
Medicines. 2018; 5(4): 126
[Pubmed] | [DOI]
33 Use of Curcumin, a Natural Polyphenol for Targeting Molecular Pathways in Treating Age-Related Neurodegenerative Diseases
Panchanan Maiti,Gary Dunbar
International Journal of Molecular Sciences. 2018; 19(6): 1637
[Pubmed] | [DOI]
34 Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer’s and Parkinson’s Diseases
Oscar Teijido,Ramón Cacabelos
International Journal of Molecular Sciences. 2018; 19(10): 3199
[Pubmed] | [DOI]
35 The Efficacy of Curcumin on Cognition, Depression, and Agitation in Older Adults with Alzheimer’s Disease
Jyotsna Sharman,Roofia Galeshi,Lisa Onega,Susanne Ashby,Kavya Sharman
The Open Nutrition Journal. 2017; 11(1): 11
[Pubmed] | [DOI]
36 Factors involved in white-to-brown adipose tissue conversion and in thermogenesis: a review
T. Montanari,N. Pošcic,M. Colitti
Obesity Reviews. 2017;
[Pubmed] | [DOI]
37 Nanoplasmonic fiber tip probe detects significant reduction of intracellular Alzheimer’s disease-related oligomers by curcumin
Feng Liang,Yu Wan,Diane Schaak,Joseph Ward,Xunuo Shen,Rudolph E. Tanzi,Can Zhang,Qimin Quan
Scientific Reports. 2017; 7(1)
[Pubmed] | [DOI]
38 Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer’s disease
K. G. Goozee,T. M. Shah,H. R. Sohrabi,S. R. Rainey-Smith,B. Brown,G. Verdile,R. N. Martins
British Journal of Nutrition. 2016; 115(03): 449
[Pubmed] | [DOI]
39 A systematic review of the relationship between behavioral and psychological symptoms (BPSD) and caregiver well-being
Alexandra Feast,Esme Moniz-Cook,Charlotte Stoner,Georgina Charlesworth,Martin Orrell
International Psychogeriatrics. 2016; : 1
[Pubmed] | [DOI]
40 Curcumin induces brown fat-like phenotype in 3T3-L1 and primary white adipocytes
Jameel Lone,Jae Heon Choi,Sang Woo Kim,Jong Won Yun
The Journal of Nutritional Biochemistry. 2016; 27: 193
[Pubmed] | [DOI]
41 In vitrostudy on potential pharmacological activity of curcumin analogues and their copper complexes
Erika Ferrari,Rois Benassi,Monica Saladini,Giulia Orteca,Zuzana Gazova,Katarina Siposova
Chemical Biology & Drug Design. 2016;
[Pubmed] | [DOI]
42 Clinicians’ prescription preferences for treating patients with Alzheimer’s disease in Shanghai
Chun-Xia Ban,Shi-Fu Xiao,Xiang Lin,Tao Wang,Qi Qiu,Min-Jie Zhu,Xia Li
Translational Neurodegeneration. 2016; 5(1)
[Pubmed] | [DOI]
43 Vitamin E, Turmeric and Saffron in Treatment of Alzheimer’s Disease
Nur Adalier,Heath Parker
Antioxidants. 2016; 5(4): 40
[Pubmed] | [DOI]
44 Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Rosaliana Libro,Sabrina Giacoppo,Thangavelu Soundara Rajan,Placido Bramanti,Emanuela Mazzon
Molecules. 2016; 21(4): 518
[Pubmed] | [DOI]
45 Curcumin and Resveratrol in the Management of Cognitive Disorders: What is the Clinical Evidence?
Gabriela Mazzanti,Silvia Di Giacomo
Molecules. 2016; 21(9): 1243
[Pubmed] | [DOI]
46 Characteristic Autonomic Nervous Activity of Institutionalized Elders with Dementia
Shoko Fuji,Tetsuya Tanioka,Yuko Yasuhara,Miki Sato,Ken Saito,Marguerite J. Purnell,Rozzano Locsin,Toshiyuki Yasui
Open Journal of Psychiatry. 2016; 06(01): 34
[Pubmed] | [DOI]
47 Clinical development of curcumin in neurodegenerative disease
Shuxin Hu,Panchanan Maiti,Qiulan Ma,Xiaohong Zuo,Mychica R Jones,Greg M Cole,Sally A Frautschy
Expert Review of Neurotherapeutics. 2015; 15(6): 629
[Pubmed] | [DOI]
48 An update on Curcuma as a functional food in the control of cancer and inflammation
Moshe Schaffer,Pamela M. Schaffer,Gil Bar-Sela
Current Opinion in Clinical Nutrition and Metabolic Care. 2015; 18(6): 605
[Pubmed] | [DOI]
49 Demographic and medication characteristics of traditional Chinese medicine users among dementia patients in Taiwan: A nationwide database study
Shun-Ku Lin,Yueh-Ting Tsai,Jung-Nien Lai,Chien-Tung Wu
Journal of Ethnopharmacology. 2015; 161: 108
[Pubmed] | [DOI]
50 Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimeræs disease
Madhuri Venigalla,Sandra Sonego,Erika Gyengesi,Matthew J. Sharman,Gerald Münch
Neurochemistry International. 2015;
[Pubmed] | [DOI]
51 Curcumin supplementation improves mitochondrial and behavioral deficits in experimental model of chronic epilepsy
Harpreet Kaur,Amanjit Bal,Rajat Sandhir
Pharmacology Biochemistry and Behavior. 2014;
[Pubmed] | [DOI]
52 Downregulation of PI3K/Akt/mTOR signaling pathway in curcumin-induced autophagy in APP/PS1 double transgenic mice
Chen Wang,Xiong Zhang,Zhipeng Teng,Tong Zhang,Yu Li
European Journal of Pharmacology. 2014;
[Pubmed] | [DOI]
53 Adenosine triphosphate concentrations are higher in the brain of APOE3- compared to APOE4-targeted replacement mice and can be modulated by curcumin
Dawn Chin,Stephanie Hagl,Annika Hoehn,Patricia Huebbe,Kathrin Pallauf,Tilman Grune,Jan Frank,Gunter P. Eckert,Gerald Rimbach
Genes & Nutrition. 2014; 9(3)
[Pubmed] | [DOI]
54 Curcumin as a Therapeutic Agent in Dementia: A Mini Systematic Review of Human Studies
Natascia Brondino,Simona Re,Annalisa Boldrini,Antonella Cuccomarino,Niccolò Lanati,Francesco Barale,Pierluigi Politi
The Scientific World Journal. 2014; 2014: 1
[Pubmed] | [DOI]
55 Chronic Neuroinflammation in Alzheimer’s Disease: New Perspectives on Animal Models and Promising Candidate Drugs
Christopher Millington,Sandra Sonego,Niloo Karunaweera,Alejandra Rangel,Janice R. Aldrich-Wright,Iain L. Campbell,Erika Gyengesi,Gerald Münch
BioMed Research International. 2014; 2014: 1
[Pubmed] | [DOI]
56 Psychopharmacologic Treatments for Alzheimer Disease and Related Dementias
Brian P. Gomoll,Brandon D. Sanders,Maria T. Caserta
Psychopharm Review. 2014; 49(1): 9
[Pubmed] | [DOI]
57 Epigenetic drug discovery for Alzheimer’s disease
Ramón Cacabelos,Clara Torrellas
Expert Opinion on Drug Discovery. 2014; : 1
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
   Case Reports
    Article Figures
    Article Tables

 Article Access Statistics
    PDF Downloaded2100    
    Comments [Add]    
    Cited by others 57    

Recommend this journal